文献速递生殖医学

孕激素方案与GnRH拮抗剂方案卵巢刺激的整倍体率相当

Euploidy rates are comparable between progestin protocol ovarian stimulation and gonadotropin-releasing hormone antagonist protocol ovarian stimulation cycles.
PubMed 文献 · Fertil Steril · 2026-04-06

本回顾性队列研究比较了孕激素方案(地屈孕酮30 mg/d)与GnRH拮抗剂方案卵巢刺激周期的囊胚整倍体率。共纳入4755个刺激周期,经倾向性评分匹配后分析973个拮抗剂周期和398个孕激素周期。多因素混合效应回归分析显示两组卵母细胞数、成熟卵母细胞数、囊胚数及整倍体囊胚数均相似,每个活检囊胚的整倍体率无显著差异,且与患者年龄无显著交互作用。

要点

  • 孕激素方案与GnRH拮抗剂方案的囊胚整倍体率相似。
  • 两组的卵母细胞数、成熟卵母细胞数、囊胚数及整倍体囊胚数均无显著差异。
  • 方案与患者年龄之间未检测到显著交互作用。

核心结论

  • 孕激素方案卵巢刺激的囊胚整倍体率与GnRH拮抗剂方案相似,为较新的孕激素方案提供了安心证据。

研究设计与样本

  • 回顾性队列研究,共纳入4755个刺激周期,经倾向性评分匹配后分析973个GnRH拮抗剂周期和398个孕激素方案周期。

主要发现

  • 双变量比较中,两组成熟卵母细胞数、受精卵数、囊胚数、整倍体囊胚数及每个活检囊胚的整倍体率均相似。
  • 多因素混合效应回归分析显示,卵母细胞数IRR 0.96(95%CI 0.89-1.03),成熟卵母细胞数IRR 0.95(95%CI 0.87-1.03),囊胚数IRR 1.12(95%CI 0.97-1.29),整倍体囊胚数IRR 1.08(95%CI 0.86-1.36)。
  • 每个活检囊胚的整倍体率在两组间相似,且方案与患者年龄之间未检测到显著交互作用。
  • 29名个体在同一日历年内先后接受两种方案刺激,两种方案的MII卵母细胞数、囊胚数及整倍体率均相似。

临床怎么用

  • 对于接受辅助生殖技术助孕的女性,孕激素方案可作为GnRH拮抗剂方案的一种替代选择,而不必担心囊胚整倍体率降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare blastocyst euploidy rates between progestin protocol ovarian stimulation and gonadotropin-releasing hormone (GnRH) antagonist protocol ovarian stimulation cycles. DESIGN: Retrospective cohort study. SUBJECTS: Women undergoing assisted reproductive technology cycles with their own oocytes. EXPOSURE: Ovarian stimulation was commenced on day 2/3 of the cycle, and either the GnRH-antagonist protocol was employed or the progestin protocol with dydrogesterone at a dose of 30 mg/d in three divided doses was started on the same day with gonadotropins or the day after and continued until (including) the day of final oocyte maturation. MAIN OUTCOME MEASURES: Blastocyst euploidy rates. RESULTS: A total of 4,755 stimulation cycles were included in the study, and 973 GnRH antagonist and 398 propensity score-matched progestin protocol cycles were included in the analyses. In bivariate comparisons, mature oocyte yield, number of zygotes, blastocysts, euploid blastocysts, and euploidy rate per biopsied blastocyst were similar between the groups. Multivariable mixed-effects regression analyses adjusted for confounders showed similar oocyte count (incidence rate ratios [IRR] 0.96, 95% confidence interval [CI] 0.89-1.03), mature oocyte count (IRR 0.95, 95% CI 0.87-1.03), blastocyst count (IRR 1.12, 95% CI 0.97-1.29), and euploid blastocyst count (IRR 1.08, 95% CI 0.86-1.36). Euploidy rate per biopsy was similar between the progestin protocol and the GnRH antagonist protocol, and no significant interaction was detected between the protocol and patient age. Twenty-nine individuals, who underwent two stimulation cycles, one with progestin protocol and another with GnRH antagonist protocol, in any order, within the same calendar year, had similar metaphase II oocyte yields, blastocyst counts, and euploidy rates with both protocols. CONCLUSION: The present study provides reassurance about the newer progestin protocol by demonstrating similar euploidy rates of blastocysts with GnRH antagonist protocols.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Ata B, Lawrenz B, Kalafat E, et al. Euploidy rates are comparable between progestin protocol ovarian stimulation and gonadotropin-releasing hormone antagonist protocol ovarian stimulation cycles. Fertil Steril. 2026. PMID: 41951202. doi:10.1016/j.fertnstert.2026.03.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。